Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $2.3 million.

  • Coherus Oncology's Interest Expenses fell 1775.73% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year increase of 2163.29%. This contributed to the annual value of $27.2 million for FY2024, which is 3301.27% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Interest Expenses is $2.3 million, which was down 1775.73% from $2.3 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Interest Expenses high stood at $18.3 million for Q4 2024, and its period low was $2.2 million during Q1 2025.
  • Over the past 5 years, Coherus Oncology's median Interest Expenses value was $5.8 million (recorded in 2021), while the average stood at $6.9 million.
  • The largest annual percentage gain for Coherus Oncology's Interest Expenses in the last 5 years was 7267.16% (2024), contrasted with its biggest fall of 7246.79% (2024).
  • Over the past 5 years, Coherus Oncology's Interest Expenses (Quarter) stood at $5.8 million in 2021, then skyrocketed by 62.01% to $9.4 million in 2022, then increased by 13.15% to $10.6 million in 2023, then skyrocketed by 72.67% to $18.3 million in 2024, then plummeted by 87.32% to $2.3 million in 2025.
  • Its Interest Expenses was $2.3 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.2 million in Q1 2025.